Präsentationen Annual Meeting 2006

J. Barrett

Approaching the In Silico Child1100_Barrett.ppt (2 MB)

B. Bernhard

Can Healthcare Systems Afford Targeted Medicines?B_Bernhard_SV_28.02.06.pdf (290 kB)

H. Fuder

Gaps Between Biomarkers and Surrogate Endpoints: CNSH._Fuder_IV_02.03.06.pdf (4 MB)

R. Krishna

Approaches to First-In-Man and Beyond: Early Evidence of Target Engagement with Biomarkers and Innovative Clinical Trial Designs.Krishna_SII_28.02.06.ppt (2 MB)

J. Lesko

Tools to Reduce Phase III Trial Failures.1500_Lesko.ppt (560 kB)

J. Lütz

Perspective of the German Medicines Agency (BfArM). BfArM after reorganisation of the structure.J._L_tz_SVII_06.03.06.pdf (151 kB)

B. Meibohm

Interplay between Drug Metabolizing EnzymesB._Meibohm_SIII_28.02.06.pdf (1 MB)

J. Schentag

The Gap Between Biomarkers and Surrogate Endpoints in the Development of Anti-Infectives.J._Schentag_SIV_01.03.06.pdf (212 kB)

B. Schug

Drug Interaction StudiesB._Schug_WS_C_09.03.06.pdf (215 kB)

S. Stürzebecher

The Feasibility of Personalized Medicine.0830_St_rzebecher.ppt (1 MB)

T. Sudhop

What is required for first into man? The EU IMPD.EU-IMPD.pdf (87 kB)

S. Throm

Innovation or Stagnation - Perspective of Pharmaceutical Industry.Throm_SVII_01.03.06.pps (463 kB)

G. Wensing

From Preclinical Data to Proof of Concept – Strategies for First to Man Studies.1200_Wensing.pdf (777 kB)

M. Zühlsdorf

The gap between biomarkers and surrogate endpoints Oncology1630_Z_hlsdorf.ppt (2 MB)

Seite aktualisiert am 14.05.2009

Sitemap | Kontakt | Impressum